0001104659-15-007835.txt : 20150209
0001104659-15-007835.hdr.sgml : 20150209
20150209163747
ACCESSION NUMBER: 0001104659-15-007835
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150205
FILED AS OF DATE: 20150209
DATE AS OF CHANGE: 20150209
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000890465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 870439579
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: (908) 450-5300
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rogus Joseph J
CENTRAL INDEX KEY: 0001299691
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23272
FILM NUMBER: 15589031
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
STREET 2: 3RD FLOOR
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
4
1
a4.xml
4
X0306
4
2015-02-05
0
0000890465
NPS PHARMACEUTICALS INC
NPSP
0001299691
Rogus Joseph J
550 HILLS DRIVE
BEDMINSTER
NJ
07921
0
1
0
0
SVP, GTO & Supply Chain Mngmt
Common Stock
2015-02-05
4
M
0
16875
8.25
A
37026
D
Common Stock
2015-02-05
4
M
0
11434
8.23
A
48460
D
Common Stock
2015-02-05
4
M
0
4313
3.34
A
52773
D
Common Stock
2015-02-05
4
S
0
32622
45.8968
D
20151
D
Employee Stock Options (right to buy)
8.25
2015-02-05
4
M
0
16875
0
D
2021-02-17
Common Stock
16875
2813
D
Employee Stock Options (right to buy)
8.23
2015-02-05
4
M
0
11434
0
D
2023-02-13
Common Stock
11434
14702
D
Employee Stock Options (right to buy)
3.34
2015-02-05
4
M
0
4313
0
D
2020-02-19
Common Stock
4313
69738
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.89 to $45.93, inclusive. The reporting person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
On February 17, 2011, the reporting person received a grant of 45,000 stock options under the Issuer's 1998 Stock Option Plan. The options became exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter.
On February 13, 2013, the reporting person received a grant of 26,136 stock options under the Issuer's 2005 Omnibus Incentive Plan. The options became exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter.
On February 19, 2010, the reporting person was granted options to purchase shares of common stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of the date of this filing, the performance criteria and the time-based criteria for 112,125 of these options has been satisfied. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.
/s/ Joseph J. Rogus, by Jill Thompson as attorney-in-fact
2015-02-09